nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas
|
Ramón y Cajal, S. |
|
|
22 |
6 |
p. 798-801 |
artikel |
2 |
Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer
|
Kirwan, C. C. |
|
|
22 |
6 |
p. 870-877 |
artikel |
3 |
Comment on “Prognostic factors and survival in Ewing’s sarcoma treated by limb salvage surgery”
|
Weng, J. |
|
|
22 |
6 |
p. 956 |
artikel |
4 |
Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
|
Remon, J. |
|
|
22 |
6 |
p. 961-962 |
artikel |
5 |
Detection of incident breast and colorectal cancer cases from an administrative healthcare database in Catalonia, Spain
|
Escribà, J. M. |
|
|
22 |
6 |
p. 943-952 |
artikel |
6 |
Detection of novel mitochondrial mutations in cytochrome C oxidase subunit 1 (COX1) in patients with familial adenomatous polyposis (FAP)
|
Afkhami, E. |
|
|
22 |
6 |
p. 908-918 |
artikel |
7 |
Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
|
Liu, R. |
|
|
22 |
6 |
p. 928-934 |
artikel |
8 |
Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis
|
Li, Z.-X. |
|
|
22 |
6 |
p. 892-899 |
artikel |
9 |
Ethical commitment of Spanish oncologists to patients with prostate cancer: reflections on the statements of the new ASTRO/AUA guideline (2019 guideline amendment)
|
Casas, F. |
|
|
22 |
6 |
p. 802-803 |
artikel |
10 |
Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy
|
Cascales Campos, P. |
|
|
22 |
6 |
p. 852-859 |
artikel |
11 |
Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis
|
Gootee, J. |
|
|
22 |
6 |
p. 860-869 |
artikel |
12 |
Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer
|
Valentí, V. |
|
|
22 |
6 |
p. 935-942 |
artikel |
13 |
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
|
Remon, J. |
|
|
22 |
6 |
p. 823-834 |
artikel |
14 |
Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
|
Consoli, F. |
|
|
22 |
6 |
p. 900-907 |
artikel |
15 |
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
|
Cortellini, A. |
|
|
22 |
6 |
p. 844-851 |
artikel |
16 |
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol
|
Salah, S. |
|
|
22 |
6 |
p. 878-883 |
artikel |
17 |
Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
|
Wang, G. |
|
|
22 |
6 |
p. 813-822 |
artikel |
18 |
Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis
|
Wang, Y. |
|
|
22 |
6 |
p. 835-843 |
artikel |
19 |
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
|
Sakakida, T. |
|
|
22 |
6 |
p. 919-927 |
artikel |
20 |
SEOR recommendations on the use of protons
|
Lloret-Saez-Bravo, M. |
|
|
22 |
6 |
p. 795-797 |
artikel |
21 |
Standardized versus research-based PAM50 intrinsic subtyping of breast cancer
|
Prat, A. |
|
|
22 |
6 |
p. 953-955 |
artikel |
22 |
The utilization of saliva as an early diagnostic tool for oral cancer: microRNA as a biomarker
|
Ghizoni, J. S. |
|
|
22 |
6 |
p. 804-812 |
artikel |
23 |
TLI in pediatric patients
|
Ocanto, A. |
|
|
22 |
6 |
p. 884-891 |
artikel |
24 |
Treatment of radiation-induced myelopathy with bevacizumab
|
Cañedo, G. |
|
|
22 |
6 |
p. 957-960 |
artikel |